BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
64.15
-2.02 (-3.05%)
Mar 6, 2026, 12:54 PM EST - Market open
BridgeBio Pharma Employees
As of December 31, 2025, BridgeBio Pharma had 839 total employees, including 834 full-time and 5 part-time employees. The number of employees increased by 109 or 14.93% compared to the previous year.
Employees
839
Change (1Y)
109
Growth (1Y)
14.93%
Revenue / Employee
$598,422
Profits / Employee
-$864,042
Market Cap
12.44B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
BBIO News
- 2 days ago - BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - GlobeNewsWire
- 9 days ago - BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates - GlobeNewsWire
- 11 days ago - BridgeBio to Participate in March Investor Conferences - GlobeNewsWire
- 16 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET - GlobeNewsWire
- 21 days ago - Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
- 21 days ago - BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript - Seeking Alpha